BIOATLA INC. - COMMON STOCK

BioAtla Announces Change in Executive Leadership

27 2月 2023 07:07:17 条件 Nasdaq GlobeNewswire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

23 2月 2023 07:00:01 条件 Nasdaq GlobeNewswire

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

10 1月 2023 07:00:02 条件 Nasdaq GlobeNewswire

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

22 12月 2022 07:00:01 条件 Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies London Healthcare Conference

08 11月 2022 07:00:03 条件 Nasdaq GlobeNewswire

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

04 11月 2022 08:08:20 条件 Nasdaq GlobeNewswire

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

03 11月 2022 15:01:01 条件 Nasdaq GlobeNewswire

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

27 10月 2022 07:00:02 条件 Nasdaq GlobeNewswire

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

09 8月 2022 15:05:01 条件 Nasdaq GlobeNewswire

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

03 8月 2022 07:00:01 条件 Nasdaq GlobeNewswire

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

02 8月 2022 07:00:03 条件 Nasdaq GlobeNewswire

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

01 6月 2022 15:05:00 条件 Nasdaq GlobeNewswire

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

04 5月 2022 15:01:01 条件 Nasdaq GlobeNewswire

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

08 4月 2022 07:00:00 条件 Nasdaq GlobeNewswire